Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Vistamedi | Healthcare Services | 20.7% | 78th pct | 268 |
| Tbilisis Tsentraluri La… | Healthcare Services | 10.6% | 53rd pct | 268 |
| Tsqaltubos Termuli Tsql… | Healthcare Services | 5.7% | 37th pct | 268 |
| Neolabi | Healthcare Services | -26.9% | 6th pct | 268 |
| Bi Parenti | Healthcare Services | -53.6% | 4th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Tbilisis Tsentraluri La… | Bi Parenti | Vistamedi | Tsqaltubos Termuli Tsql… | Neolabi |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 38.8% | -19.0% | 100.0% | 100.0% | 74.2% |
| EBITDA Margin | 10.6% | -53.6% | 20.7% | 5.7% | -26.9% |
| EBITDAR | 318 | -1,450 | 651 | 145 | -516 |
| EBITDAR Margin | 10.6% | -50.2% | 24.7% | 5.7% | -22.0% |
| EBIT Margin | 10.6% | -53.9% | 16.8% | -70.8% | -46.9% |
| Net Profit Margin | 10.5% | -56.5% | 15.5% | -66.4% | -27.4% |
| Operating Expense % of Sales | 28.2% | 34.7% | 79.3% | 94.3% | 101.1% |
| Returns | |||||
| Return on Assets (ROA) | 34.1% | -87.7% | 35.2% | -29.4% | -10.1% |
| Return on Equity (ROE) | 118.4% | N/A | 39.6% | -29.7% | -10.4% |
| ROIC [EBIT / Invested Capital] | 120.9% | N/A | 47.2% | -35.0% | -19.8% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | -0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | N/A | 0.00x | 0.00x | N/A |
| Equity-to-Assets | 28.8% | -76.9% | 88.9% | 98.8% | 97.1% |
| Net Debt | -4 | -106 | -95 | -529 | -585 |
| Cash & Equivalents | 4 | 106 | 95 | 529 | 585 |
| Total Debt | N/A | N/A | N/A | N/A | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 1.05x | 0.55x | 4.49x | 9.00x | 3.14x |
| Quick Ratio | 0.68x | 0.55x | 4.49x | 8.00x | 3.14x |
| Cash Ratio | 0.01x | 0.03x | 0.73x | 7.45x | 3.14x |
| Total Current Assets | 692 | 1,806 | 581 | 639 | 585 |
| Total Current Liabilities | 659 | 3,292 | 129 | 71 | 186 |
| Inventory | 244 | N/A | N/A | 71 | N/A |
| Trade Receivables | 444 | 1,651 | 63 | 6 | 142 |
| Trade Payables | N/A | 87 | 66 | 61 | 170 |
| Net Working Capital | 33 | -1,486 | 452 | 568 | 399 |
| Net Working Capital % of Revenue | 1.1% | -51.4% | 17.1% | 22.2% | 17.0% |
| Trade Working Capital | 688 | 1,564 | -3 | 16 | -28 |
| Trade Working Capital % of Revenue | 22.9% | 54.1% | -0.1% | 0.6% | -1.2% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 7.52x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 48.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 6.75x | 1.75x | 41.84x | 426.67x | 16.53x |
| Days Sales Outstanding (DSO) | 54.0 | 208.5 | 8.7 | 0.9 | 22.1 |
| Payables Turnover | N/A | 39.65x | N/A | N/A | 3.56x |
| Days Payable Outstanding (DPO) | N/A | 9.2 | N/A | N/A | 102.6 |
| Cash Conversion Cycle | 102.6 days | 199.3 days | 8.7 days | 0.9 days | -80.6 days |
| Asset Turnover | 3.24x | 1.55x | 2.27x | 0.44x | 0.37x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 706 | N/A | 21 | 242 | -193 |
| Free Cash Flow (OCF − Capex proxy) | 623 | N/A | 21 | -1,030 | -189 |
| Cash Conversion (OCF / EBITDA) | 222.0% | N/A | 3.8% | 166.9% | N/A |
| Dividends Declared | 600 | N/A | N/A | 0 | N/A |
| Dividend Payout Ratio | 189.9% | N/A | N/A | N/A | N/A |